Despite decades of surveillance and pharmaceutical and non-pharmaceutical interventions,
seasonal influenza viruses continue to cause epidemics around the world each year. The …

Antibody responses are essential for protection against influenza virus infection. Humans
are exposed to a multitude of influenza viruses throughout their lifetime and it is clear that …

The ability for viruses to mutate and evade the human immune system and cause infection,
called viral escape, remains an obstacle to antiviral and vaccine development …

The imperfect effectiveness of seasonal influenza vaccines is often blamed on antigenic
mismatch, but even when the match appears good, effectiveness can be surprisingly low …

Seasonal coronaviruses (OC43, 229E, NL63, and HKU1) are endemic to the human
population, regularly infecting and reinfecting humans while typically causing asymptomatic …

Influenza virus can escape most antibodies with single mutations. However, rare antibodies
broadly neutralize many viral strains. It is unclear how easily influenza virus might escape …

Preexisting antibodies to endemic coronaviruses (CoV) that cross-react with SARS-CoV-2
have the potential to influence the antibody response to COVID-19 vaccination and infection …

Humans are repeatedly exposed to influenza virus via infections and vaccinations.
Understanding how multiple exposures and pre-existing immunity impact antibody …

Influenza A viruses evolve rapidly to escape host immunity, causing reinfection. The form
and duration of protection after each influenza virus infection are poorly understood. We …

Seroepidemiology, the use of data on the prevalence of bio‐markers of infection or
vaccination, is a potentially powerful tool to understand the epidemiology of infection before …